



## SuperGen to Webcast Investigator/Analyst Pipeline Update Presentation October 24

DUBLIN, Calif., Oct. 18 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that it will webcast its investigator/analyst pipeline update presentation beginning at 7:50 p.m. PDT on Wednesday, Oct. 24, 2007 in San Francisco.

The presentations will include corporate and scientific updates by SuperGen and its collaborators, with specific information on the company's clinical and drug discovery programs.

This event will include the following presenters:

- Gregory Berk, M.D., SuperGen's Chief Medical Officer
- David Bearss, Ph.D., SuperGen's Chief Scientist
- Peter Jones, M.D., Director of the UCS/Norris Comprehensive Cancer Center
- Tony Tolcher, M.D., Director of Clinical Trials for South Texas Accelerated Research Therapeutics (START).

The presentations will be webcast live and can be accessed via the Investor Relations section of SuperGen's Web site at [www.supergen.com](http://www.supergen.com). A webcast replay will be available for 90 days following the live event.

### About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit <http://www.supergen.com>.

### Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

#### Contacts

Timothy L. Enns  
SuperGen, Inc.  
SVP, Corporate Communications  
& Business Development  
Tel: (925) 560-0100  
E-mail: [tenns@supergen.com](mailto:tenns@supergen.com)

Mary M. Vegh  
SuperGen, Inc.  
Manager, Investor Relations  
Tel: (925) 560-2845  
E-mail: [mary.vegh@supergen.com](mailto:mary.vegh@supergen.com)

SOURCE SuperGen, Inc. 10/18/2007

Web site: <http://www.supergen.com>  
(SUPG)

